HT receptors expressed throughout the human body are targets for established therapeutics
and various drugs in development. Their diversity of structure and function reflects the …

Psychiatric disorders represent a large economic burden in modern societies. However,
pharmacological treatments are still far from optimal. Drugs used in the treatment of major …

Cognitive impairment is a key feature of schizophrenia and may be the most important
determinant of outcome in schizophrenia. This impairment is diffuse and may reflect …

According to World Health Organization estimates, 5% of the adult population worldwide
suffers from depression. In addition to the affective, psychomotor and cognitive symptoms …

In obsessive–compulsive disorder (OCD), the success of pharmacological treatment with
serotonin re-uptake inhibitors and atypical antipsychotic drugs suggests that both the central …

Quetiapine (Seroquel®), a dibenzothiazepine derivative, is an atypical antipsychotic with
demonstrated efficacy in acute schizophrenia. In short-term, randomised, double-blind trials …

In previous studies, we demonstrated that tandospirone, a serotonin-5-HT1A partial agonist,
added to ongoing treatment with small to moderate doses of typical antipsychotic drugs …

OBJECTIVE: The authors examine the functional anatomy of serotonergic and dopaminergic
systems in obsessive-compulsive disorder in psychotropic-naive patients without …

Objective To review the evidence that agents which preferentially affect serotonin (5-HT)
attenuate the ability of N-methyl-D-aspartate (NMDA) receptor non-competitive antagonists …

The first compounds showing efficacy in the treatment of schizophrenia and other psychotic
disorders was chlorpromazine, an anti-histaminic compound casually observed to possess …